Author

Cyril Gaultier

OpenAlex ID: A5122832081

Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial

2026 · Chloe Orkin, Chloe Orkin, et al. · The Lancet · 5

Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial

2026 · Amy E Colson, Princy N Kumar, et al. · The Lancet · 3

Changing to a once-a-day single pill of bictegravir/lenacapavir from complex HIV treatment: a plain language summary of the ARTISTRY-1 study up to 1 year

2026 · Chloe Orkin, Peter J. Ruane, et al. · Figshare

Changing to a once-a-day single pill of bictegravir/lenacapavir from complex HIV treatment: a plain language summary of the ARTISTRY-1 study up to 1 year

2026 · Chloe Orkin, Peter J. Ruane, et al. · Future Virology

Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

2026 · Eric G Meissner, Eric G Meissner, et al. · The Lancet HIV

P-387. Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Cabotegravir + Rilpivirine: Results From the Phase 4 EMPOWER Study

2026 · Samir K Gupta, Thomas C S Martin, et al. · Open Forum Infectious Diseases

Works count: 7

Citation count: 13

H-index: 3

I10-index: